SCHEMBL1375795

SCHEMBL1375795

CCOC(=O)C1CC1(OC(C)C)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
OPRM1 P35372 5/20 0.40
OPRD1 P41143 3/20 0.39
OPRK1 P41145 3/20 0.39
SLC22A1 O15245 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
KCNH2 Q12809 1/20 0.39
KDM4E B2RXH2 2/20 0.38
PKM P14618 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3972482 0.83 CCR2 (0.38) ALDH1A1HTTTSHRMEN1KMT2A
SCHEMBL29688113 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL21439250 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL29688152 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL23375509 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL6081939 0.77 LMNA (0.51) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL15978552 0.76 L3MBTL1 (0.49) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL15978556 0.76 L3MBTL1 (0.49) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL15977390 0.76 L3MBTL1 (0.49) ALDH1A1L3MBTL1HTTTSHRMEN1
SCHEMBL15977383 0.76 L3MBTL1 (0.49) ALDH1A1L3MBTL1HTTTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4764888-B2 2011-09-07 JP claimed
CN-101142167-A Compounds that stimulate glucose utilization and methods of use UNIV ALBERTA (CA) 2008-03-12 CN claimed
EP-1868982-A2 COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE The Governors of the University of Alberta (CA) 2007-12-26 EP claimed
WO-2006117686-A2 COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2006-11-09 WO claimed
US-20050182133-A1 Compounds that stimulate glucose utilization and methods of use UNIVERSITY OF ALBERTA (CA) 2005-08-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182133-A1 Compounds that stimulate glucose utilization and methods of use GPR119, SLC2A4, SLC2A1 ALDH1A1 1918/4885L3MBTL1 4705/4885HTT 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.